A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year ...

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote ...

Once-weekly retatrutide reduced body weight by an average of 20.8% at the highest dose and lowered hemoglobin A 1C (HbA 1C) ...

At the Community Oncology Alliance Payer Exchange & Innovation Summit in September, a panel of statistical experts posed a ...

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, ...

Weighted average monthly Medicare Advantage (MA) premiums are projected to fall 16.5% in 2027, while average premiums for ...

Any weekend catch-up sleep was independently associated with lower OAB odds (adjusted OR 0.79; 95% CI 0.67–0.93) after ...

Open-source oncology tools span patient-facing trackers and explainers, genomics-to-therapy ranking systems, and LLMs ...

Before defining a network meta-analysis, Dr. Citrome walks through the statistical fundamentals that make one useful. He ...

Incremental outcomes favored tirzepatide (4.46 QALYs; $190,270) and semaglutide (3.04 QALYs; $243,094) versus resmetirom (3.47 QALYs; $948,743), driving large ICER separation.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Specialty pharmacy workflows—access, education, interaction checks, toxicity management—mitigate BTK antiplatelet risks and ...